A pivotal study of LX 1004
Latest Information Update: 14 Jan 2021
At a glance
- Drugs LX 1004 (Primary)
- Indications Neuronal ceroid lipofuscinosis
- Focus Registrational; Therapeutic Use
- Sponsors LEXEO Therapeutics
- 14 Jan 2021 New trial record
- 07 Jan 2021 According to a LEXEO Therapeutics media release, this trial is expected to begin in 2022.